Lipoxin A₄, CAS 89663-86-5, is a potent inhibitor of cytotoxic activity of human natural killer cells. Shown to be as potent as LTB4 in stimulating human neutrophils to generate superoxides.
Caution! Product contains volatile liquid. Keep product cold at all times.
Potent inhibitor of cytotoxic activity of human natural killer cells; shown to be as potent as LTB4 in stimulating human neutrophils to generate superoxides. Involved in contractile responses and acts as a potent activator of human protein kinase C. Stimulates rapid lipid remodeling and pertussis-sensitive release of arachidonic acid in polymorphonuclear leukocytes. Stimulates MAP kinases via activation of G protein-coupled receptors.
生化/生理作用
Cell permeable: no
Primary Target Potent inhibitor of cytotoxic activity of human natural killer cells
Product does not compete with ATP.
Reversible: no
警告
Toxicity: Flammable (J)
外形
In Ethanol.
重悬
Following initial thaw, aliquot and freeze (-70°C).
其他说明
Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.
McMahon, B., et al. 2000. J. Biol. Chem. 275, 27566. Soyombo, O., et al. 1994. Allergy 49, 230. Flore, S., et al. 1992. J. Biol. Chem.267, 16168. Badr, K.F., et al. 1989. Proc. Natl. Acad. Sci. USA86, 3438.
法律信息
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Proceedings of the National Academy of Sciences of the United States of America, 86(9), 3438-3442 (1989-05-01)
Lipoxin A4 (LXA4) was competitive with [3H]leukotriene D4 (LTD4) for specific binding to cultured rat glomerular mesangial cells. Half-maximal inhibition was obtained with 100 nM LXA4, compared with 10 nM for unlabeled LTD4. At 10 and 50 nM LXA4 induced
The Journal of biological chemistry, 275(36), 27566-27575 (2000-06-28)
The lipoxygenase-derived eicosanoids leukotrienes and lipoxins are well defined regulators of hemeodynamics and leukocyte recruitment in inflammatory conditions. Here, we describe a novel bioaction of lipoxin A(4) (LXA(4)), namely inhibition of leukotriene D(4) (LTD(4))-induced human renal mesangial cell proliferation, and
Lipoxins are trihydroxytetraene metabolites derived through a double lipoxygenation of arachidonic acid. Lipoxin A4 (LXA4) was prepared by total chemical synthesis, and its capacity to modulate eosinophil migration has been evaluated. LXA4 is a weak and partial chemotactic agent; at
The Journal of biological chemistry, 267(23), 16168-16176 (1992-08-15)
Lipoxin A4 stimulates rapid lipid remodeling and a pertussis toxin-sensitive release of arachidonic acid in polymorphonuclear leukocytes (PMN) (Nigam, S., Fiore, S., Luscinskas, F.W., and Serhan, C.N. (1990) J. Cell. Physiol. 143, 512-523) and has been shown to inhibit leukocyte